Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 02/28/2026 | 11/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 39.15% | -24.11% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 39.15% | -24.11% | |||
| Cost of Revenue | -34.40% | 0.81% | |||
| Gross Profit | 54.03% | -27.75% | |||
| SG&A Expenses | 17.21% | -12.36% | |||
| Depreciation & Amortization | 2.35% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.78% | -10.81% | |||
| Operating Income | 5.51% | -0.30% | |||
| Income Before Tax | 15.64% | -11.47% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 15.64% | -11.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15.64% | -11.47% | |||
| EBIT | 5.51% | -0.30% | |||
| EBITDA | 5.84% | -0.22% | |||
| EPS Basic | 14.81% | 0.00% | |||
| Normalized Basic EPS | -7.14% | 17.65% | |||
| EPS Diluted | 14.81% | 0.00% | |||
| Normalized Diluted EPS | -7.14% | 17.65% | |||
| Average Basic Shares Outstanding | 0.81% | 9.04% | |||
| Average Diluted Shares Outstanding | 0.81% | 9.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||